PET Radioligands for Imaging of Tau Pathology: Current Status

Area of Science:

• Neuroscience
• Radiochemistry
• Medical Imaging

Background:

• Alzheimer's disease (AD) incidence is rising globally, posing significant social and economic challenges.
• Effective disease-modifying treatments for AD are still under development, with many in clinical trials.
• Early and accurate diagnosis is critical for improving patient prognosis, especially as treatments may be most effective in early disease stages.

Purpose of the Study:

• To review lead radioligands developed for Alzheimer's disease (AD) imaging.
• To present preclinical data of these radioligands.
• To facilitate the development of novel tau-specific positron emission tomography (PET) radioligands for early AD diagnosis.

Main Methods:

• Literature review of published preclinical studies on radioligands for AD.
• Analysis of radioligand characteristics and performance metrics.
• Focus on tau-specific tracers for PET imaging.

Main Results:

• Several promising radioligands targeting tau pathology in AD have been identified.
• Preclinical data indicate varying degrees of target specificity, affinity, and brain penetration.
• The review synthesizes key findings to guide future development.

Conclusions:

• Tau-specific PET radioligands hold significant promise for early and accurate Alzheimer's disease (AD) diagnosis.
• Continued research and development are essential to optimize these tracers for clinical application.
• Improved diagnostic tools are vital for advancing AD treatment strategies.